Poly(β-amino ester)s are cationic degradable polymers that have significant potential as gene delivery vectors. Here we present a generalized method to modify poly(β-amino ester)s at the chain ends to improve their delivery performance. End-chain coupling reactions were developed so that polymers could be synthesized and tested in a high-throughput manner, without the need for purification. In this way, many structural variations at the polymer terminus could be rapidly evaluated. Endmodification of the terminal amine structure of a previously optimized poly(β-amino ester), C32, significantly enhanced its in vitro transfection efficiency. In vivo, intraperitoneal (IP) gene delivery using end-modified C32 polymers resulted in expression levels over one order of magnitude higher than unmodified C32 and jetpolyethylenimine (jet-PEI) levels in several abdominal organs. The rapid end-modification strategy presented here has led to the discovery of many effective polymers for gene delivery and may be a useful method to develop and optimize cationic polymers for gene therapy.
INTRODUCTION
Increased attention has been focused on the development and use of cationic polymers as gene transfection agents. [1] [2] [3] eir ability to interact electrostatically with plasmid DNA and self-assemble into cationic nanoparticles has made them useful in a variety of gene therapy applications. 4 e most commonly used polymer is polyethylenimine (PEI). 5, 6 Despite its widespread use, PEI su ers from several disadvantages that currently limit its utility, such as high cytotoxic e ects, lack of degradability, and low gene delivery e ciency relative to viruses. 7, 8 e poly(β-amino ester)s are a new class of cationic, degradable polymers that have demonstrated signi cant promise as transfection agents. 9, 10 Poly(β-amino ester)s are synthesized by the conjugate addition of amines to diacrylate monomers. e polymer molecular weight and end-chain functionality can be controlled by varying the monomer ratios, reaction time, and temperature. 11 Previous studies have shown both of these polymer properties to be critical for e cient transfection. 11 In general, the polymer molecular weight must be high enough to facilitate DNA binding and nanoparticle formation but also low enough to permit DNA unpackaging inside the nucleus.
e functional group at the chain end has been shown to a ect both cytotoxicity and cellular uptake of polymer-DNA complexes. 11 Recent studies show that the amine-terminated polymers are generally more e ective at promoting cellular uptake and DNA delivery than their acrylatecapped counterparts. 11, 12 In light of these ndings, a large library of high-molecularweight, amine-terminated poly(β-amino ester)s was synthesized and screened for gene delivery. 12 e polymer with the highest gene transfer e ciency, C32, is synthesized by mixing 1,4-butanediol diacrylate (C) with 5-amino-1-pentanol (32) at a 1.2:1.0 amine: diacrylate molar ratio. Polymerization under these conditions at elevated temperature yields aminopentanol-terminated polymer chains with a weight average molecular weight of ~18 kd (relative to polystyrene standards). e C32 polymer has shown excellent biocompatibility in vivo and e ectiveness as a gene delivery vector for the treatment of prostate cancer via intra-tumoral injection. 13 Although it is generally established that the amine-terminated poly(β-amino ester)s are more e cient polymers, 11, 12 the type of amine molecule at the end of the chain has not been examined. We present here a generalized method for synthesizing poly(β-amino ester)s with terminal amines di erent from those used in the polymerization. Reaction conditions were optimized so that the end-modi ed polymers could be synthesized and tested for gene delivery rapidly, without the need for puri cation. is has enabled us to explore many structurally diverse end-modi cations and nd new poly(β-amino ester)s with improved gene delivery properties.
Using these methods, we synthesized a library of end-modi ed C32 polymers. We show here that structural variations in the terminal amine signi cantly a ect the in vitro cellular delivery of DNA. End-modi ed C32 polymers also yielded high expression levels in vivo a er intraperitoneal (IP) injection of polymer-DNA complexes. In most cases, end-modi ed C32 polymers proved more e ective at delivering DNA than unmodi ed C32 and jet-PEI, with order-of-magnitude di erences seen in almost every organ examined. ese results suggest that terminal modi cation may be a general method for the rapid optimization of poly(β-amino ester)s for gene delivery.
RESULTS

Polymer synthesis
Amine-capped polymers were prepared using C32 as a common backbone. is polymer was synthesized in previous studies using butanediol diacrylate (C) and aminopentanol (32) monomers in a 1.2:1.0 amine:diacrylate molar ratio to generate aminopentanol-terminated polymer chains. High-throughput synthesis and screening studies have identi ed this combination of monomers as yielding the best-performing poly(β-amino ester) to date for gene delivery. 12 erefore, we selected these two monomers in the design of our next-generation amine-terminated polymers. e synthesis involved an initial polymerization with excess diacrylate monomer to produce acrylate-terminated C32 polymer (C32-Ac), followed by an amine-capping step to yield C32 polymers terminated with di erent amine compounds, as outlined in Figure 1 .
e synthesis of C32-Ac was performed by mixing the C and 32 monomers in a 1.2:1.0 molar ratio at 90 °C for 24 hours (Figure 1a ). e resulting polymer had a weight average molecular weight of 8,800 d (relative to polystyrene standards), with a polydispersity of 1.9, as determined by gel permeation chromatography. e structure of the C32-Ac polymer was veri ed by 1 H nuclear magnetic resonance (NMR) and showed several characteristic acrylate peaks between 5.9 and 6.4 ppm at the chain ends.
Amine-terminated C32 polymers for in vitro screening experiments were generated by reacting C32-Ac with amine compounds in dimethyl sulfoxide (DMSO) as shown in Figure 1b .
e amine-capping reagents were selected for structural diversity, DMSO solubility, and biocompatibility (Figure 2) . In this way, the e ects of hydrophobicity/hydrophilicity, carbon chain length, and functional groups (e.g., hydroxyl, primary amine) at the amine terminus could be systematically assessed. Capping reactions proceeded to completion overnight at room temperature using a 1.6-fold molar excess of amine over acylrate end groups, as shown by 1 H NMR. e excess of amine was necessary to cap the polymer chain and prevent crosslinking as a result of newly formed secondary amines, as determined by 1 H NMR and gel permeation chromatography measurements. In addition, the excess amine not incorporated at the chain ends did not interfere with subsequent polymer transfections or a ect COS-7 cell viability (as determined by comparing C32 and C32 with an added quantity of excess amine; data not shown). As such, these reaction conditions allowed for the rapid, parallel synthesis of amine-capped C32 polymers in DMSO without the need for puri cation. By conducting the reaction at a 100 mg/ml concentration in DMSO, polymers could be diluted with sodium acetate bu er and used directly in transfection assays without any DMSO-induced toxicity.
14 Amine-terminated polymers for in vivo gene delivery experiments were synthesized by a slightly modi ed route that permitted isolation of pure polymers. For the amine-capping step, the reaction was conducted in tetrahydrofuran (THF) using the same concentrations and reaction time as the DMSO-based protocol. Pure polymers were then isolated by precipitation in diethyl ether, which e ectively extracted any excess, unreacted amine and THF solvent, as determined by 1 H NMR analysis. Before use, dried polymers were dissolved in DMSO.
Polymer transfections
e transfection ability of amine-terminated C32 polymers was quanti ed in a high-throughput protocol using 96-well plates. 15 Unlike in previous poly(β-amino ester) studies, transfections were performed in the presence of 10% serum. [12] [13] [14] Transfection e ciencies, measured as luciferase enzyme activity and expressed as relative light units, are shown in Figure 3 . e wide range in luciferase expression indicates that the terminal amine has a large e ect on poly(β-amino ester)-mediated transfections. In general, the most e ective polymers have hydrophilic end groups containing primary or tertiary amines. Polymers demonstrating the lowest transfection levels generally consist of a hydrophobic end group containing either an alkyl chain or an aromatic ring.
Interestingly, C32-32 (i.e., a C32 polymer terminated with aminopentanol) is structurally identical to C32 but has a 35% lower transfection e ciency. We attribute this disparity to the molecular weight di erences between these polymers. Specically, C32 (1.2:1.0 ratio) has a molecular weight of 18,100 d and is twofold more e cient than a 6,670 d C32 polymer synthesized using a 1.3:1.0 ratio of monomers. 12 In the present study, C32-32 was determined to have a molecular weight of ~8,800 d. Although the reasons for these di erences in activity are unknown, the www.moleculartherapy.org vol. 15 no. 7 july 2007 © The American Society of Gene Therapy lower-molecular-weight C32-32 polymer may have a reduced capacity to self-assemble with plasmid DNA into nanoparticles su cient for cellular uptake, as observed for other, structurally similar poly(β-amino ester)s.
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In addition to the overall transfection ability, the amine end group has a pronounced e ect on the optimum polymer:DNA ratio. In general, polymers capped with primary diamine compounds maintain high levels of DNA delivery at much lower polymer:DNA ratios than mono-amine-terminated polymers. is e ect is particularly evident with C32-108, which can transfect cells at the same level as C32 but at a polymer:DNA ratio that is vefold lower (100:1 versus 20:1). Seven polymers terminated with primary diamines had optimum transfection levels at this reduced polymer:DNA weight ratio, and one polymer, C32-110, was optimal at the lowest weight ratio tested.
IP gene delivery
On the basis of the results of cell transfection experiments, we selected nine polymers (C32-66, -87, -99, -103, -106, -116, -117, -121, and -122) to test for in vivo gene delivery in mice. All polymers tested in vivo resulted in signi cant gene delivery and protein expression in the abdominal region a er IP administration. With the exception of C32-87, all end-modi ed C32 polymers proved more e ective than C32 and jet-PEI in whole-body scans. Whole-body images are shown in Figure 4a for the top-performing polymers (C32-103, -116, -117, and -122) and for C32 and jet-PEI positive controls. e four modi ed C32 polymers yielded higher expression than unmodi ed C32 and jet-PEI ( Figure 5) . Average whole-body expression levels observed in mice treated with amine-capped C32 polymers were at least 175-fold higher than those in bu er-injected control mice. C32-103 delivery was the most e cient, yielding expression that was ~500-fold higher.
ese modi ed polymers also delivered DNA 4-to 12-fold more e ciently than C32 and 15-to 42-fold more e ciently than jet-PEI. Even though we tested a limited set of polymers, a convergence in structure seems apparent for the top performers. e most e ective polymers (C32-103, -116, and -117) are terminated with primary diamine molecules that contain a three-carbon spacer between amine functionalities, but di er in the degree and pattern of substitution at the interior carbons.
We also tested the duration of luciferase expression a er DNA delivery with C32 and C32-117 (Figure 4b ). Mice were optically imaged 1, 4, and 9 days a er IP administration of polymer-DNA complexes. Maximal luciferase expression was observed for C32-delivered DNA 1 day a er injection. C32-117-delivered DNA had highest expression 4 days a er administration and remained at high levels at day 9. At each time point, C32-117-delivered DNA was expressed at signi cantly higher levels than C32-delivered DNA as determined using t-tests. We also observed low levels of luciferase expression 2 months a er administration of C32-117-DNA complexes (data not shown).
A er whole-body imaging and analysis, organs were harvested from the mice and imaged to determine the biodistribution of polymer-DNA transfection a er IP administration. Luciferase expression levels were quanti ed from these images, and the results are shown in Figure 5 for the four best-performing endmodi ed C32 polymers, C32, and jet-PEI. Mean transfection levels are shown, with statistical di erences between modi ed C32 polymers and C32 determined using one-way analysis of variance tests (P < 0.05) for each tissue. For each organ, C32 and jet-PEI delivered DNA with similar e ciencies. Tranfection levels for these polymers were mostly within one order of magnitude of those for the untreated control mice. e end-modi ed C32 polymers showed higher expression levels than both C32 and jet-PEI, with at least one polymer showing an order-of-magnitude increase over C32 in every organ tested. In fact, C32-117 was capable of mediating these di erences in every organ except the prostate and spleen, in which it was one-to fourfold more e ective than C32. Order-of-magnitude-higher transfection levels over jet-PEI were also observed with C32-103 in every organ except the kidney and spleen. ese results demonstrate that altering the functionality at the ends of poly(β-amino ester)s can substantially improve in vivo gene delivery performance.
e levels of gene expression in each organ varied considerably among the amine-terminated polymers. e C32-103, -116, and -117 polymers di er slightly in end-group structure but displayed di erent transfection levels in several organs. For example, in bladder, spleen, and kidney, C32-117 delivers DNA 5-to 65-fold more e ciently than do C32-103 and -116. Interestingly, the opposite e ect is seen in the prostate, where both C32-103 and -116 are sevenfold more e ective than C32-117. ese results demonstrate that subtle structural di erences at the chain ends have signi cant e ects on the organ distribution of polymer-DNA complexes.
is suggests that polymer end-modi cation may be a useful strategy in the design of targeted delivery systems, provided the attachment of the targeting agent does not compromise transfection ability.
IV gene delivery
e ability of C32 polymers to mediate gene delivery via an intravenous (IV) route was investigated by administering tail vein injections of polymer-DNA complexes. For these experiments, only half the amount of polymer-DNA complex was used as for IP delivery, but in the same volume. Initial experiments showed that 50 µg is the maximum amount of DNA that mice could tolerate by IV administration of the polymer-DNA complexes.
An initial screening experiment was performed with the same nine polymers used in the IP screens. For the nine polymers tested, tail vein injection of the polymer-DNA complexes resulted in low levels of gene expression compared with levels attained a er IP administration. Whole-body images showed that most expression occurred in the side, chest, and upper leg for each polymer (data not shown). Similar to the IP delivery studies, C32-103 and C32-117 emerged as the most e cient polymers a er IV delivery.
Quantitative measurements of transfection in whole-body images and harvested organs a er IV injection were performed for C32-117, C32, and jet-PEI. e measured relative light unit values as a function of the transfected organ for each polymer are shown in Figure 6 . Although C32 and C32-117 showed low overall gene expression, both showed signi cant expression in spleen compared with bu er-treated control mice. C32-117 showed additional expression in the lungs, at levels elevated over those in bu er-injected control mice, but signi cantly lower than those mediated by jet-PEI.
DISCUSSION
In this study, we present a general method for the functionalization of poly(β-amino ester)s through a selective end-chain modi cation. We further show that these modi cations alter the e ciency and speci city with which polymers deliver DNA to several organs a er systemic administration of polymer-DNA complexes to mice.
Preparation of end-modi ed polymers involves an initial synthesis of acrylate-terminated polymer chains followed by the conjugation of aminated molecules to these acrylate end groups. One signi cant advantage of this approach is the speci c reactivity of the acrylates with amines, which permits many other functional groups such as hydroxyls, ethers, amides, and aromatics to be incorporated into the side chains and end groups without any complex protection/deprotection steps. 14 is speci city in acrylate reactivity, coupled with the commercial availability of many di erent amine molecules, makes it possible to produce many end-modi ed variants of a single diacrylate-terminated polymer. In addition, the synthetic conditions employed for the aminecapping step were optimized at room temperature, in the absence of a catalyst, and with only a slight excess of amine, so that the nal end-modi ed polymers can be tested in cells without puri cation.
is approach enables the parallel synthesis of many structurally diverse, end-modi ed polymers under conditions that allow them to be easily incorporated into high-throughput in vitro protocols for assessing gene delivery e ciency.
Although an end-modi cation strategy is particularly advantageous for the development of functionalized poly(β-amino ester)s, few studies report similar methods for modifying other polycationic vectors. For the most common polymers, such as PEI, the backbone and/or side chains have been frequently used to conjugate targeting ligands, polyethyleneglycol chains, and a variety of small molecules because these sites contain a high density of reactive amine nucleophiles. [16] [17] [18] End-modi cations have been performed on these polymers, but the high reactivity of interior functionalities necessitates a multi-step synthetic approach in which the inner amines are protected during the end-chain reaction. 19 In these cases, almost all gene delivery applications to date have focused on the conjugation of polyethyleneglycol chains to improve blood stability and/or targeting agents to promote cellspeci c delivery. [19] [20] [21] [22] We demonstrate here that the terminal functionality greatly a ects the transfection e ciency of the C32 poly(β-amino ester). Hydrophilic amines containing hydroxyl or additional amine groups proved to be the most e ective capping agents. e average C32 in vitro transfection e ciency was improved by almost 30% by conjugating ethylenediamine to the ends (C32-102) instead of aminopentanol (C32). Some modi cations also signi cantly reduce the amount of polymer necessary for optimal tranfection.
High transfection levels were observed a er IP injection of polymer-DNA complexes. End-modi ed polymers resulted in whole-body reporter protein expression more than an order-ofmagnitude higher than that for jet-PEI. ey also outperformed the best poly(β-amino ester) synthesized to date, C32, with overall Figure 6 Intravenous (IV) gene delivery in mice. Quantification of luciferase expression in whole body and individual organs 6 hours after IV injection of polymer-DNA complexes in FVB/J mice. Results are expressed as mean transfection levels (± SD) for a buffer control (white), C32-117 (green), C32 (pink), and jet-polyethylenimine (jet-PEI) (black). n 3 for each treatment group. RLU, relative light unit.
expression levels 4-to 12-fold higher. We found sustained expression past 1 week both with modi ed C32 and with C32, but modied C32 was expressed at sign cantly higher levels, re ecting its enhanced delivery capabilities. Perhaps the most surprising nding was that very subtle structural di erences in the end-amine signi cantly altered the tissue expression pattern. is e ect was most evident between the C32-116 and C32-117 polymers, where the latter displayed 5-to 65-fold higher delivery to the bladder, spleen, liver, and kidney. e only di erence between these two diaminopropane end-capping reagents is the ethyl versus dimethyl branching.
IP gene delivery may provide a strategy for the treatment of a variety of diseases, including cancer. Ovarian, pancreatic, and gastric cancers may be particularly amenable to this approach. [23] [24] [25] ere is generally a poor prognosis associated with these cancers owing to (i) the di culty in diagnosis, (ii) the lack of symptoms in early stages, and (iii) the generally low response to chemotherapeutic treatments. 26, 27 In the late stages, metastasis occurs, and the cancer can spread throughout the peritoneum. Several studies have shown a positive response and suppression of cancer growth using both viral and non-viral IP gene delivery approaches. [28] [29] [30] [31] [32] e poly(β-amino ester)s described here may be have advantages for these applications over the current delivery systems as they o er degradability, low cytotoxicity, and high expression relative to other non-viral systems.
Although IP gene delivery was very e ective with the endoptimized poly(β-amino ester)s, lower expression was observed a er IV administration.
e only notable di erence was an improvement in lung delivery by C32-117 over C32. e reasons for their reduced delivery properties are not clear, but one possibility relates to the serum stability of the polymer-DNA complexes. In vitro screening was performed in cell culture medium containing 10% serum. Although the polymers proved highly e ective under these conditions, their in vitro transfection eciency in the absence of serum proteins is fourfold higher (data not shown). It is possible that the high concentration of serum proteins present a er IV injection shields, disrupts, or otherwise unfavorably interacts with polymer-DNA complexes and limits delivery. Gra ing polyethyleneglycol or other inert polymers may be a bene cial strategy to improve poly(β-amino ester) stability in the circulation, as shown for other polycationic materials. 33, 34 
MATERIALS AND METHODS
Materials. PEI (water free, M w ~ 25 kd, M n ~ 10 kd), anhydrous DMSO, and anhydrous THF were purchased from Sigma-Aldrich (St. Louis, MO). Jet-PEI was purchased from Polyplus Transfection (Illkirch, France). A 25 mM sodium acetate bu er solution, pH 5.2 (NaAc bu er), was prepared by diluting a 3 M stock (Sigma-Aldrich). e 1,4-butanediol diacrylate (99%+) and 5-amino-1-pentanol (97%) were from Alfa Aesar (Ward Hill, MA). Amine-capping reagents were purchased from SigmaAldrich, Alfa Aesar, Acros Organics/Fisher Scienti c (Pittsburgh, PA), TCI America (Portland, OR), Molecular Biosciences (Boulder, CO), and Toronto Research Chemicals (Ontario, Canada). All chemicals were used as received without any further puri cation. pCMV-Luc plasmid DNA stock solution (1 mg/ml in water) was obtained from Elim Biopharmaceuticals (Hayward, CA). pCAG/luc plasmid DNA 35 was prepared using a Qiagen maxi-plamid prep kit (Valencia, CA). White polystyrene tissueculture-treated 96-well plates were obtained from Corning Costar (Lowell, MA). Clear polystyrene tissue-culture-treated 96-well plates were obtained from Becton Dickinson (Bedford, MA). Polypropylene 96-well deep-well plates were purchased from Sigma-Aldrich.
Cell culture. COS-7 cells were obtained from American Type Culture Collection (Manassas, VA) and grown at 37 °C, 5% CO 2 , in phenol redfree DMEM supplemented with 10% fetal bovine serum and 100 U/ml of penicillin/streptomycin.
Mice. Six-week-old male FVB/J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were 8-10 weeks of age at the time of nanoparticle administration. Hemizygous MISIIR/TAg male transgenic mice 36 were bred to C57BL/6J females (Jackson Laboratory) to generate hemizygous MISIIR/TAg female mice. Ovarian tumors were detected by palpation. All procedures on mice were done in accordance with protocols approved by the Lankenau Institutional Animal Care and Use Committee.
NMR.
1 H NMR was conducted on a Varian Inova 500 MHz spectrometer.
Synthesis of acrylate-terminated poly(β-amino ester)s. C32-Ac was synthesized by mixing 793 mg of 1,4-butanediol diacrylate ("C" 4 mmol) with 344 mg of 5-amino-1-pentanol ("32" 3.3 mmol) in a Te on-lined screw-cap vials containing a magnetic stir bar.
e mixture was stirred at 90 °C for 24 hours, cooled to room temperature, and used immediately for subsequent capping reactions. Method 2. Acrylate-terminated polymer C32-Ac was dissolved in THF at 31.13% wt/wt. Amine-capping reagents were dissolved in THF at 0.25 M nal concentration. End-chain capping reactions were performed by mixing 321 mg of polymer/THF solution with 800 µl of amine solution in Te on-lined screw-cap vials with magnetic stirring overnight. Endmodi ed polymers were precipitated by the addition of 10 volumes of diethyl ether and centrifugation at 2,500 rpm for 2 minutes. Polymers were washed with 5 ml of ether twice and dried overnight in a vacuum desiccator. Dried polymers were dissolved at 100 mg/ml in DMSO and stored at −20 °C until used for each experiment.
In vitro transfections. COS-7 cells (15,000 cells/well) were plated in white 96-well plates and allowed to adhere overnight. Polymers at 100 mg/ml in DMSO were diluted accordingly into NaAc bu er to concentrations that yielded the di erent polymer:DNA weight ratios. Diluted polymer solution (100 µl) was mixed vigorously with 100 µl of DNA (60 µg/ml in NaAc bu er) in a 96-well polystyrene plate. e solutions were le undisturbed for 5 minutes, a er which time 120 µl of each was added to 800 µl of cell www.moleculartherapy.org vol. 15 no. 7 july 2007 © The American Society of Gene Therapy culture medium in a deep-well polypropylene plate. e medium over the cells was then removed with a 12-channel aspirator wand, followed by the addition of 150 µl/well of polymer-DNA complex solution. Complexes were incubated with the cells for 1 hour, a er which time they were aspirated o and replaced by 105 µl/well of fresh cell culture medium. Cells were allowed to grow for 3 days at 37 °C, 5% CO 2 , and were then analyzed for luciferase enzyme activity.
Luciferase activity was analyzed using Bright-Glo assays kits (Promega, Madison, WI). In brief, 100 µl/well of Bright-Glo solution was added to the cell plates. e plates were gently agitated to promote mixing for 2 minutes. Luminescence was then measured on a Mithras Luminometer using a 1% neutral density lter and a 1 second per well counting time.
IP administration. To prepare polymer-DNA complexes, 100 µg pCAG/ luc DNA in 50 µl H 2 O was mixed with 50 µl diluted polymer [20-30 µl polymer (1 mg/10 µl stock) diluted in 50 mM NaAc bu er, pH 5.2] to yield, a polymer:DNA ratio of 20:1 to 30:1. A er a 5-minute incubation at room temperature, 20 µl of a 30% (wt/vol) solution of glucose in phosphate-bu ered saline was added to the polymer-DNA mixture (5% glucose nal concentration). e resulting 120 µl volume was injected immediately into the peritoneal cavity of a mouse using a 28-gauge 0.5-inch insulin syringe.
IV administration. Polymer-DNA complexes were prepared in the same manner as for IP administration except that only 50 µg pCAG/luc DNA in 50 µl H 2 O was mixed with 50 µl diluted polymer [10-15 µl polymer (1 mg/10 µl stock) diluted in 50 mM NaAc bu er, pH 5.2]. A er incubation at room temperature for 5 minutes, glucose in phosphate-bu ered saline was added. A 28-gauge 0.5-inch insulin syringe was used to inject complexes slowly into the tail vein.
Optical imaging. Optical bioluminescence imaging was performed on whole bodies of mice, harvested organs, and tumors 6 hours a er injection (unless otherwise indicated) of polymer-DNA complexes using an IVIS imaging system (Xenogen, Alameda, CA) as previously described. 13 LIVE IMAGE acquisition and analysis so ware (Xenogen, Alameda, CA) was used to quantify luciferase expression from the optical images. Statistical di erences between modi ed C32 polymers and C32 were determined using one-way analysis of variance with a Tukey Kramer multiple comparison test on log-transformed data (*P < 0.05; **P < 0.01; ***P < 0.001).
